Signaling networks and cell cycle control : the molecular basis of cancer and other diseases /
Cellular control mechanisms.
| Other Authors: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Totowa, N.J. :
Humana Press,
[2000]
|
| Series: | Cancer drug discovery and development ;
5. |
| Subjects: |
Table of Contents:
- Integrin signaling
- Signal transduction through tyrosine kinase growth factor receptors
- Signaling from TGF-beta receptors
- The WNT signal transduction pathway
- Signaling from G-protein-coupled receptors to the nucleus
- Proximal events in T-cell activation
- Signal transduction from the high affinity IgE receptor
- Signaling through Fas (CD95, APO-1) and related death receptors
- Signal transduction to the nucleus by MAP kinase
- The regulation of MAP kinase pathways by MAP kinase phosphatases
- Control of MAPK signaling by Ste20- and Ste 11-like kinases
- Ras signaling and transformation
- Signaling pathways controlled by Rho family GTP-binding proteins
- P13-kinases: role in signal transduction
- P13K-related kinases: roles in cell-cycle regulation and DNA damage responses
- Integrative signaling through c-Abl: a tyrosine kinase with nuclear and cytoplasmic functions
- Src: a model for regulation of intracellular signaling molecules
- Inhibitors of protein kinase C and related receptors for the lipophilic second messenger sn-1,2-diacylglycerol
- Reactive oxygen species in proliferative signaling
- Sphingolipid metabolites in signal transduction
- The Jak/Stat signaling cascade: its role in the biological effects of interferons
- Regulation of cell growth and death by p53
- Regulation of NF-kB function: novel molecular targets for pharmacological intervention
- Using protein-interaction domains to manipulate signaling pathways
- Protein tyrosine kinase inhibitors as novel therapeutic agents
- A pharmacological approach to the MAP kinase cascade
- Specific inhibitors of p38 MAP kinase
- Farnesyltransferase inhibitors: anti-ras or anticancer drugs?
- Targeted p53 gene therapy-mediated radiosensitization and chemosensitization
- Treatment of p53-deficient cancers by adenovirus E1B-region mutants: from basic research to the clinic
- The cell cycle inhibitor p27 as a prognostic marker in human tumors and a novel target for therapeutic intervention
- Chemical cyclin-dependent kinase inhibitors: therapeutic implications.